$1M Cash Deal: Noveris Health Sciences to Acquire 49% Stake in Stem Cell Distributor
summarizeSummary
Noveris Health Sciences has signed a term sheet to acquire a 49% equity interest in ELL Stem Cells, a private British Columbia-based stem cell distributor, for USD $1 million in cash. This significant transaction, which includes an option to acquire the remaining 51% via common shares, marks a major strategic pivot for Noveris into the regenerative medicine distribution market. For a company with a market capitalization of approximately $1.23 million, the $1 million cash outlay for a minority stake is highly material, representing a substantial financial commitment and a new business direction. While the move into FDA-registered stem cell distribution could offer growth, investors will closely watch the execution of the definitive agreement, due diligence, and the potential dilutive impact of acquiring the remaining interest. The company also clarified a minor error in previously disclosed finder's fees.
At the time of this announcement, MYCOF was trading at $1.00 on OTC in the Life Sciences sector, with a market capitalization of approximately $1.2M. The 52-week trading range was $0.01 to $1.40. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: The newswire.ca.